A Phase 2 interventional study of Low-dose naltrexone and acetaminophen combination and Placebo in Chronic Low Back Pain and Lumbar Radiculopathy, sponsored by Allodynic Therapeutics, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by Allodynic Therapeutics, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.
Among the 126 studies in Radiculopathy with a site in United States, this one is the 94th largest by enrollment of the 106 interventional ones that give a count, is one of 5 that started in 2017, is one of 10 in phase 2, and was the 59th registered.
484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.
Browse Radiculopathy studies →29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:
Liberty University · Sites in United States
Ages 18+
Vertanical GmbH · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Northwestern University · Sites in United States, Thailand, Ukraine
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17 · Phase 3 19 · Phase 4 9
First in 2001; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 60 across 374 interventional studies indexed under Radiculopathy.
Median enrollment 78 across the 106 interventional studies, 54 across the 20 observational. Of the 73 that completed or were terminated, 29 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 126 have an industry lead sponsor. The 10 most frequent:
Allodynic Therapeutics, Inc is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Allodynic Therapeutics, Inc has 1 study filed under Radiculopathy — fewer than ten, so there is no comparison to draw.
12 of the studies in Radiculopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT03023696The Cleveland ClinicCan Prophylactic Foraminotomy Prevent C5 Palsy | 2026-12 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT07397117University of California, San FranciscoComparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care | 2026-12-31 |
| NCT04982965University of California, San DiegoBrain Mechanisms Supporting Cannabis-induced Pain Relief | 2027-01-15 |
Add all 12 to your calendar (.ics) → With an account.
Among the 126 studies in Radiculopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Treatment of chronic low-back pain with low-dose naltrexone and acetaminophen combination: a small, randomized, double-Blind, and placebo-controlled clinical trial with an open-label extension for none-responders
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient has concomitant migraine unless he/she treats migraine attacks only with ergotamine or triptans.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Low-dose naltrexone and acetaminophen combination
Drug: Placebo
Drug pages: Naltrexone · Acetaminophen
Twice a day
Twice a day
The change from baseline in mean 7-day, 24-hour Worst Pain Intensity (WPI).
The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime. The WPI score is measured on the 11-point (0-10) Numeric Rating Scale (NRS), (0=no pain, 10=worst possible pain).
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
The change from baseline in mean 7-day, 24-hour Average Pain Intensity (API).
The mean weekly API score will be derived from assessments recorded by patients daily at bedtime. The API score is measured on the 11-point (0-10) NRS.
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
Proportion of patients with 50% or more reduction in 7-day, 24-hour Worst Pain Intensity (WPI).
The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime. The WPI score is measured on the 11-point (0-10) NRS.
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
The change from baseline in mean 7-day, 24-hour Right Now Pain Intensity (NPI).
The mean weekly NPI score will be derived from assessments recorded by patients daily at bedtime. The NPI score is measured on the 11-point (0-10) NRS.
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
The change from baseline in mean 7-day, 24-hour Pain-Related Interference (PRI) with day-to-day activities.
The mean weekly PRI score will be derived from assessments recorded by patients daily at bedtime. The PRI score is measured on the 11-point (0-10) NRS.
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
The change from baseline in mean 7-day, 24-hour pain-related sleep interference (PRSI).
The mean weekly PRSI score will be derived from assessments recorded by patients daily at bedtime. The PRSI score is measured on the 11-point (0-10) NRS.
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
Change from baseline in the mean number of rescue medications used.
Rescue medications use will be derived from daily recordings by patients.
Time frame: From baseline to the last 7 days of the 12-week treatment period.
Change from baseline in the mean Oswestry Disability Index (ODI).
Patients will complete the ODI instrument during site visits (%).
Time frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
Change from baseline in the mean Pittsburgh Insomnia Rating Scale-20 (PIRS-20).
Patients will complete the PIRS-20 instrument during site visits (0-60).
Time frame: From baseline to the last 7 days of a 12-week double-blind treatment period.
Comparison of the proportion of patients who experienced adverse events.
Defined as any untoward medical occurrences, regardless of their suspected cause.
Time frame: Completion of the treatment period at 12 weeks.
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Jul 2018, 11 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Naltrexone · Acetaminophen
Allodynic Therapeutics, Inc